174 related articles for article (PubMed ID: 29112001)
1. A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.
Anta L; Llaudó J; Ayani I; Martínez J; Litman RE; Gutierro I
Int Clin Psychopharmacol; 2018 Mar; 33(2):79-87. PubMed ID: 29112001
[TBL] [Abstract][Full Text] [Related]
2. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1).
Llaudó J; Anta L; Ayani I; Martínez J; Schronen J; Morozova M; Ivanov M; Gutierro I
Int Clin Psychopharmacol; 2016 Nov; 31(6):323-31. PubMed ID: 27416102
[TBL] [Abstract][Full Text] [Related]
3. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
Thyssen A; Rusch S; Herben V; Quiroz J; Mannaert E
J Clin Pharmacol; 2010 Sep; 50(9):1011-21. PubMed ID: 20097933
[TBL] [Abstract][Full Text] [Related]
4. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
[TBL] [Abstract][Full Text] [Related]
5. The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study.
Walling DP; Hassman HA; Anta L; Ochoa L; Ayani I; Martínez J; Gutierro I
Drug Des Devel Ther; 2021; 15():4371-4382. PubMed ID: 34703212
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study.
Filts Y; Litman RE; Martínez J; Anta L; Naber D; Correll CU
Schizophr Res; 2022 Jan; 239():83-91. PubMed ID: 34847501
[TBL] [Abstract][Full Text] [Related]
7. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
8. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
10. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.
Bai YM; Chen TT; Lin WK; Chang WH; Wu B; Hung CH; Chou P; Chen JY
J Clin Psychopharmacol; 2007 Jun; 27(3):306-8. PubMed ID: 17502783
[No Abstract] [Full Text] [Related]
12. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
[TBL] [Abstract][Full Text] [Related]
14. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia.
Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907
[TBL] [Abstract][Full Text] [Related]
18. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
[TBL] [Abstract][Full Text] [Related]
19. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
Risinger R; Hard M; Weiden PJ
Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
[TBL] [Abstract][Full Text] [Related]
20. Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review.
Álamo C
Adv Ther; 2022 Nov; 39(11):4875-4891. PubMed ID: 36048404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
